Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1/2 1

Status

Recruiting 8Active not recruiting 4Terminated 2Not yet recruiting 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Head & Neck 1

Conditions

Breast Neoplasms 303Carcinoma, Non-Small-Cell Lung 240Prostatic Neoplasms 196Neoplasms 190Lung Neoplasms 149Multiple Myeloma 141Neoplasm Metastasis 110Colorectal Neoplasms 104Melanoma 97Ovarian Neoplasms 90Leukemia, Myeloid, Acute 82Pancreatic Neoplasms 76Lymphoma 76Leukemia, Lymphocytic, Chronic, B-Cell 71Brain Neoplasms 69Carcinoma, Renal Cell 67Squamous Cell Carcinoma of Head and Neck 62Lymphoma, Non-Hodgkin 62Carcinoma, Hepatocellular 61Hematologic Neoplasms 60Urinary Bladder Neoplasms 58Head and Neck Neoplasms 56Triple Negative Breast Neoplasms 55Recurrence 54Glioblastoma 53Uterine Cervical Neoplasms 51Lymphoma, Follicular 51Endometrial Neoplasms 50Stomach Neoplasms 46Sarcoma 46

Interventions

dehydroftorafur 1Watchful Waiting 1Taxes 1Radiotherapy, Intensity-Modulated 1Platinum 1Paclitaxel 1Gemcitabine 1Fluorouracil 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Epstein-Barr Virus Infections × 90 days × Clear all
NCT07536048 2026-05-19

A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years

Sanofi

Active not recruiting
100 enrolled

Epstein-Barr Virus Infections

NCT02135042 2026-05-07

Individualized Treatment Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA

NRG Oncology

Phase 2/3 Active not recruiting
685 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Epstein-Barr Virus Infections

NCT05164094 2026-05-06

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 30-Year-Old Healthy Adolescents and Adults

ModernaTX, Inc.

Phase 1/2 Active not recruiting
867 enrolled

Infectious Mononucleosis, Epstein-Barr Virus Infections

NCT04554914 2026-04-27

A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Pierre Fabre Medicament

Phase 2 Active not recruiting
190 enrolled
LymphoidSarcoma

Immunologic Deficiency Syndromes, Leiomyosarcoma, Lymphoproliferative Disorders, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡